Breast cancer treatment decisions are based, amongst other patient- and tumor characteristics, on the expression of the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2)1. Here, PGR is linked to neoplasm.